Nkarta, Inc. (NKTX)

Market Cap	126.43M
Revenue (ttm)	n/a
Net Income (ttm)	-102.61M
Shares Out	71.03M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,988
Open	1.770
Previous Close	1.780
Day's Range	1.770 - 1.770
52-Week Range	1.310 - 3.155
Beta	0.81
Analysts	Strong Buy
Price Target	13.25 (+644.38%)
Earnings Date	Nov 10, 2025

About NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTX
• Website: https://www.nkartatx.com

Analyst Summary

According to 5 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $13.25, which is an increase of 644.38% from the latest price.

Price Target

$13.25

(644.38% upside)

Analyst Consensus: Strong Buy